BhavanaKondaMD

Oncology • Columbus, OH

Physician

Join to view full profile

Dr. Konda is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Konda's full profile

Already have an account?

Office
2050 Kenny Rd
Tower 10th Floor
Columbus, OH 43221
Phone+1 614-293-8629

Fax+1 614-293-3112

Education & Training

Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2012 - 2015
University of Miami Hospital and Clinics/Holy Cross HospitalResidency, Internal Medicine, 2009 - 2012
Osmania Medical College NTR UHSClass of 2007

Certifications & Licensure

OH State Medical License 2015 - 2026
FL State Medical License 2009 - 2013
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer Start of enrollment: 2020 Feb 10
Active, not recruiting
Phase 2

Publications & Presentations

PubMed

145 citations
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2,...
Vivek Subbiah, Jürgen Wolf, Bhavana Konda, Hyunseok Kang, Alexander Spira
The Lancet. Oncology. 2022-10-01
23 citations
Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon.
Jarred Burkart, Dwight H. Owen, Manisha H. Shah, Sherif Abdel-Misih, Sameek Roychowdhury
Journal of the National Comprehensive Cancer Network. 2018-09-01
10 citations
Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors.
Renuka Iyer, Bhavana Konda, Christos Fountzilas, Sarbajit Mukherjee, Dwight H. Owen
Cancer. 2020-08-15

Journal Articles

Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors
Neil Saunders, David Strosberg, Jill Onesti, Carl R Schmidt, Manisha Shah, Mary Dillhoff, Lawrence A Shirley, Bhavana Konda, Annals of Surgical Oncology

Lectures

First real-world experience of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET) since US FDA approval.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Preview of the 93rd American Thyroid Association Annual MeetingJuly 1st, 2024